COVID-19
MSN Labs initiates Phase-III clinical trials for COVID-19 treatment drug
Hyderabad/UNI: MSN Laboratories Private Limited, the front-runner in introducing various drugs in the treatment of COVID-19 and its complications, on Tuesday announced that it is initiating phase III clinical trials of ‘Molnupiravir’ capsules for the treatment of COVID-19 in India.
MSN had earlier received its clinical trial approval from Drugs Controller General of India (DCGI) to perform Molnupiravir Capsules efficacy and safety study on mild to moderate COVID-19 patients, Hyderabad-based MSN said in a release here.
MSN will start its clinical trials in more than 40 sites across India and the first dosing is expected to begin soon.
The clinical trials will be performed on more than 2400 subjects suffering from mild to moderate COVID-19.
Molnupiravir is an experimental drug having antiviral properties and is currently under clinical stage study for COVID-19 treatment.
MSN R&D team has developed both the API and Formulation, and is expecting to launch soon after successful conclusion of clinical study followed by regulatory approval.
As part of the COVID-19 treatment range, MSN has already launched Favilow (Favipiravir) in the strengths of 200 mg, 400 mg & 800 mg, OSELOW (Oseltamivir) as 75 mg capsules and licensed Baridoz (Baricitinib) recently with Eli Lilly.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
